S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:SRNE

Sorrento Therapeutics (SRNE) Stock Forecast, Price & News

$0.31
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$0.28
$0.32
50-Day Range
$0.20
$0.37
52-Week Range
$0.16
$3.09
Volume
1.64 million shs
Average Volume
52.69 million shs
Market Capitalization
$147.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Sorrento Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,784.6% Upside
$9.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.09
Upright™ Environmental Score
News Sentiment
0.59mentions of Sorrento Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.82) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

619th out of 983 stocks

Biological Products, Except Diagnostic Industry

99th out of 164 stocks


SRNE stock logo

About Sorrento Therapeutics (NASDAQ:SRNE) Stock

Sorrento Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company specializes in developing antibody-based therapies for cancer, autoimmune diseases, and chronic pain. Sorrento Therapeutics was founded in 1989 and has since grown into a  player in the biopharmaceutical industry, focusing on developing innovative and personalized therapies for patients.

The management team at Sorrento Therapeutics is led by Dr. Henry Ji, who serves as the company's Chairman and CEO. Dr. Ji has over 20 years of experience in the biopharmaceutical industry and has played a vital role in developing innovative Sorrento Therapeutics therapies. Other notable team members are Mike Royal, Chief Medical Officer, who has over 20 years of clinical development experience and Dr. Robert D. Allen, who has over 15 years of biotechnology industry research and preclinical development experience. 

Over the past few years, Sorrento Therapeutics has reported relevant growth in revenue. However, the company has also reported significant losses increasing year over year. The company's debt levels have varied dramatically, with assets and liabilities increasing year over year. Sorrento Therapeutics has undergone substantial changes in ownership over the past few years, with several prominent investors increasing their stakes in the company. Sorrento Therapeutics' valuation metrics align with industry peers, with a price-to-book ratio near industry averages. However, the company's price-to-earnings ratio is currently negative, typical for clinical-stage biopharmaceutical companies that have yet to reach profitability. Sorrento Therapeutics stock has been volatile in recent years, with significant price movements and changes in trading volume. The company's stock price has steadily declined over the past five years.

The biopharmaceutical industry is highly competitive, with many large, established companies and smaller, innovative players like Sorrento Therapeutics. High research and development spending levels, lengthy regulatory approval processes, and significant intellectual property protections characterize the industry. Sorrento Therapeutics faces competition from established players such as Pfizer, Merck, and Bristol-Myers Squibb, as well as smaller biotechs developing similar antibody-based therapies.

Sorrento Therapeutics has several potential growth opportunities, including developing its proprietary antibodies and other therapies for treating cancer, autoimmune diseases, and chronic pain. The company is also exploring partnerships and collaborations with other companies in the biopharmaceutical industry to help accelerate the development of its pipeline of therapies. Additionally, Sorrento Therapeutics is expanding into new markets, focusing on Asia, with significant demand for innovative treatments.

The biopharmaceutical industry is highly regulated, and Sorrento Therapeutics may face challenges in obtaining regulatory approval for its therapies. The company's financial performance has also been volatile, with significant losses reported in recent years. Sorrento Therapeutics will need to continue investing heavily in research and development to maintain its competitive position in the industry, which may strain the company's financial resources. In addition, the biopharmaceutical industry is subject to significant geopolitical and regulatory risks, which could impact Sorrento Therapeutics' operations and growth prospects.

Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Sorrento Therapeutics, Inc. (SRNEQ)
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Why Sorrento Therapeutics Stock Is Soaring Today
Sorrento Therapeutics Files For Bankruptcy
Sorrento Therapeutics Stock Is Sinking: What's Going On?
See More Headlines

SRNE Price History

SRNE Company Calendar

Today
6/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
Employees
799
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,502.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-428,330,000.00
Net Margins
-818.22%
Pretax Margin
-877.48%

Debt

Sales & Book Value

Annual Sales
$60.32 million
Book Value
$0.26 per share

Miscellaneous

Free Float
459,611,000
Market Cap
$147.23 million
Optionable
Optionable
Beta
1.95

Social Links


Key Executives

  • Henry H. Ji
    Chairman, President & Chief Executive Officer
  • Shawn Sahebi
    Senior Vice President-Commercial Operations
  • Elizabeth Adkins Czerepak
    Chief Financial Officer & Executive Vice President
  • Mike A. Royal
    Chief Medical Officer
  • Robert D. Allen
    Senior Vice President-Research & Development













SRNE Stock - Frequently Asked Questions

Should I buy or sell Sorrento Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRNE shares.
View SRNE analyst ratings
or view top-rated stocks.

What is Sorrento Therapeutics' stock price forecast for 2023?

2 brokers have issued 1 year price objectives for Sorrento Therapeutics' stock. Their SRNE share price forecasts range from $5.00 to $13.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 2,784.6% from the stock's current price.
View analysts price targets for SRNE
or view top-rated stocks among Wall Street analysts.

How have SRNE shares performed in 2023?

Sorrento Therapeutics' stock was trading at $0.8860 at the beginning of the year. Since then, SRNE shares have decreased by 64.8% and is now trading at $0.3120.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Jane Street Group LLC (0.00%), HAP Trading LLC (0.00%), HighTower Advisors LLC (0.00%) and Cutler Group LLC CA (0.00%). Insiders that own company stock include Henry Ji and Kim Janda.
View institutional ownership trends
.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $0.31.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $147.23 million and generates $60.32 million in revenue each year.

How many employees does Sorrento Therapeutics have?

The company employs 799 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759.

This page (NASDAQ:SRNE) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -